How long dengue vaccine protection lasts in areas where dengue is common
Official title: Long-term durability of DENV-specific immunity after vaccination in a dengue-endemic population
Funded at University of Rhode Island · NIH-11309098 · Data updated 2026-11-12
This project looks at immune responses after dengue vaccination to find which people keep protection longest in places where dengue is common.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Rhode Island NIH-funded |
| Lab location | 1 site (Kingston, United States) |
| Project start | March 6, 2024 |
| Project end | February 28, 2029 |
| Funding year | 2026 |
| Award (this year) | $567,169 |
| NIH project number | 5U01AI179523-03 |
| Project ID | NIH-11309098 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates are people from dengue-endemic areas who previously received the CYD-TDV dengue vaccine in a clinical trial and can provide or have provided follow-up blood samples.
✕Less likely to help
People who have never received a dengue vaccine or cannot provide blood samples are unlikely to directly participate or benefit from this project.
What this research studies
Researchers are studying blood samples from people who received the CYD-TDV dengue vaccine to understand why some people keep antibody protection for many years while others do not. They will examine B and T immune cells, measure antibody levels, and use gene-expression and epigenetic tests (like ATAC-seq) on dengue-specific cells collected soon after vaccination. The team will link those early immune signatures to long-term antibody persistence using samples from a phase III trial cohort followed since 2011. Results aim to point to markers that predict lasting protection and inform better vaccine or booster decisions.
Why it matters
Potential benefit: If successful, this work could identify immune markers that predict long-lasting protection and guide who may need booster shots or improved vaccines.
How similar studies have gone: A licensed dengue vaccine (CYD-TDV) and other vaccine trials exist, but applying detailed cell-level transcriptomic and epigenetic profiling to predict long-term immunity is a relatively new approach.
Where this research is happening
-
University of Rhode Island
Kingston, United States Active
Researchers
- Principal investigator: Rothman, Alan L — University of Rhode Island
- Study coordinator: Rothman, Alan L
Related research
Other NIH-funded projects on the same topics.
-
Protective dengue vaccines that steer T and B cell responses
A vaccine study aims to guide the body’s T and B cells to fight all four dengue virus types safely and effectively.
-
How the immune system responds to dengue vaccines and infection
This project compares immune reactions in people given different dengue vaccine formulations to find why one vaccine fully prevented DENV-2 infection while another did not.
-
How prior dengue infections shape T cell responses after a new infection or vaccine
This project looks at how a person’s existing dengue immunity affects their body's T cell response when exposed to a different dengue serotype or a live dengue vaccine, with a focus on kids and how this influences protection and safety.
-
Protective immunity after dengue infections and vaccination
Researchers are studying how our immune system remembers dengue and how vaccines influence that protection, aiming to spot clues that predict who remains protected or at risk after infection or vaccination.
-
Dengue vaccine-B cell and T cell responses linked to protection after controlled dengue infection
A Johns Hopkins-led study will look at how the body’s B and T cells respond to dengue vaccines and how these responses relate to protection against dengue infection in people who participate in a controlled infection model.
-
How past dengue infection or vaccination shapes T cell immunity
This project looks at how previous dengue infections or a weakened dengue vaccine change T cells in children and others exposed to dengue.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.